PALO
ALTO, Calif., Jan. 8, 2024
/PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading
precision oncology company, and Hikma Pharmaceuticals PLC
("Hikma"), a multinational pharmaceutical company, today announced
an agreement to promote Guardant Health's portfolio of liquid and
tissue biopsy tests for cancer screening, recurrence monitoring and
tumor mutation profiling for all solid cancers across the
Middle East and North Africa (MENA).
The partnership expands Guardant Health's global presence and
includes products across the cancer care continuum. The tests
offered include Shield™ for cancer screening and early detection,
Guardant Reveal™ for minimal residual disease detection and
recurrence monitoring and Guardant360® and Guardant360
TissueNext™ for comprehensive genomic profiling across all solid
cancers. This agreement provides Hikma with exclusive
rights to commercialize Guardant Health's products in a majority of
countries in the MENA region.
Guardant Health serves more than 60 countries globally with its
tests, and this partnership with Hikma will improve access to
Guardant's next-generation sequencing (NGS) tests in the
Middle East and North Africa, where cancer cases are estimated
to double by the year 2040.[1]
"Guardant Health is excited to partner with Hikma and leverage
their strong commercial capabilities and regional expertise to
equip oncologists in MENA with the necessary tools for cancer
screening, recurrence monitoring and guiding treatment selection,"
said Simranjit Singh, Guardant
Health AMEA CEO. "We are committed to improving patient outcomes
globally by offering next-generation sequencing tests across all
stages of the disease. Today, an increasing number of patients with
cancer are being detected at the advanced stage, making it more
crucial to match these patients to appropriate therapies in a
timely manner. Ultimately, our goal is to make cancer screening
easy and effective so that we can detect cancer earlier when it's
most treatable."
"Our partnership with Guardant Health adds next-generation
sequencing diagnostics that can potentially transform cancer care
in MENA bringing hope to patients facing this challenging journey.
We are excited to partner with Guardant Health, as their offering
can help patients at all stages of the disease – from screening to
monitoring cancer recurrence to guiding treatment decisions. As a
leading healthcare company in MENA with a robust oncology portfolio
encompassing generics, biologics, immunotherapy, and cutting-edge
innovations, Hikma is committed to advancing precision medicine for
improved treatment outcomes in patients with cancer," said Mazen
Darwazah, Hikma's Executive Vice Chairman and President of
MENA.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated
BBB-/stable S&P and BBB-/positive Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 45 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and
expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,800
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit: www.hikma.com
Reference
1. Mahdi H, Mula-Hussain L, Ramzi ZS, et al. Cancer Burden Among
Arab-World Females in 2020: Working Toward Improving Outcomes. JCO
Glob Oncol. 2022;8:e2100415. doi:10.1200/GO.21.00415
View original content to download
multimedia:https://www.prnewswire.com/news-releases/guardant-health-and-hikma-partner-to-offer-cancer-screening-and-comprehensive-genomic-profiling-tests-in-the-middle-east-and-north-africa-302028144.html
SOURCE Guardant Health